# 2025-04107: FDA Yanks Plug on Four Forgotten Drugs No Longer for Sale

2025-04107, Bausch & Lomb Incorporated, et al.; Withdrawal of Approval of Four Abbreviated New Drug Applications, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-03-14, effective 2025-04-14; PRIA reads it as touching household money (as of 2026-09-30).

- Canonical: https://policyrisk.com/federal-register/2025-04107
- As of: 2026-09-30
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-04107
- Title: Bausch & Lomb Incorporated, et al.; Withdrawal of Approval of Four Abbreviated New Drug Applications
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 12163
- Published: 2025-03-14
- Effective: 2025-04-14
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-09-30

## In one line

FDA Yanks Plug on Four Forgotten Drugs No Longer for Sale

## Summary

The FDA is officially pulling the plug on four drug approvals from Bausch & Lomb, American Regent, and KubsTech because these medicines aren’t being sold anymore. This change kicks in on April 14, 2025, but companies can try again if they want. If you’re involved with these drugs, get ready for the update and plan accordingly!

## Abstract

The Food and Drug Administration (FDA or Agency) is withdrawing approval of four abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

## Effects PRIA read

- Four ANDA approvals withdrawn April 14, 2025: cost, medium. The FDA is withdrawing approval of four abbreviated new drug applications (ANDAs) effective April 14, 2025: ANDA 040065 (Prednisolone Sodium Phosphate 0.11% drops) from Bausch & Lomb; ANDA 202031 (Gemcitabine injectable, EQ 200 mg and EQ 1 g vials) and ANDA 202562 (Dactinomycin injectable, 0.5 mg/v…
- Existing inventories may still be dispensed: benefit, medium. Drug products listed in the withdrawal table that are in inventory on April 14, 2025 may continue to be dispensed until those inventories are depleted, reach their expiration dates, or otherwise become violative, whichever occurs first. This allows pharmacies and hospitals to use on-hand stock for…
- Companies can refile; withdrawals are without prejudice: benefit, low. The applicants requested the withdrawals and waived their opportunity for a hearing; FDA states the withdrawal of approval under 21 CFR 314.150(c) is without prejudice to refiling. That means the listed applicants may refile ANDAs for these products in the future if they choose.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-04107 on federalregister.gov](https://www.federalregister.gov/documents/2025/03/14/2025-04107/bausch-and-lomb-incorporated-et-al-withdrawal-of-approval-of-four-abbreviated-new-drug-applications)
- [2025-04107 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-03-14/pdf/2025-04107.pdf)

## Related
- [Previous: 2025-04106, Bausch & Lomb Incorporated, et al.; Withdrawal of Approval of Eight Abbreviated…](https://policyrisk.com/federal-register/2025-04106)
- [Next: 2025-04108, Notice of Request To Release Airport Property; Liberal Mid-America Regional Air…](https://policyrisk.com/federal-register/2025-04108)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-04107 (as of 2026-09-30).
